Periodic Oxaliplatin Administration in Synergy with PER2‐Mediated PCNA Transcription Repression Promotes Chronochemotherapeutic Efficacy of OSCC

Abstract Developing chemotherapeutic resistance affects clinical outcomes of oxaliplatin treatment on various types of cancer. Thus, it is imperative to explore alternative therapeutic strategies to improve the efficacy of oxaliplatin. Here, it is shown that circadian regulator period 2 (PER2) can p...

Full description

Bibliographic Details
Main Authors: Qingming Tang, Mengru Xie, Shaoling Yu, Xin Zhou, Yanling Xie, Guangjin Chen, Fengyuan Guo, Lili Chen
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.201900667